BL-8040: Additional Phase IIa data

Data from 16 evaluable patients with relapsed or refractory AML in the first 4 cohorts of an open-label, dose-escalation, U.S. and Israeli Phase IIa trial showed that doses of up to 1.25 mg/kg subcuta...